ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response

Molecular Pain

Albert Dahan²  Anthony Cerami¹  Ann Dunne¹  Michael Brines¹  Leon Aarts²  Marieke Niesters²  Monique van Velzen²  Maarten Swartjes² 

[1] Araim Pharmaceuticals, Tarrytown, NY 10591, USA;Department of Anesthesiology, Leiden University Medical Center, P5-Q, 2300 RC Leiden, The Netherlands

关键词: GFAP;    Astrocytes;    Iba-1;    Microglia;    Dorsal horn;    Allodynia;    Spared nerve injury;    ARA 290;   

Others  :  861830
DOI  :  10.1186/1744-8069-10-13

 received in 2013-08-22, accepted in 2014-02-10,  发布年份 2014

【 摘 要 】

Background

Neuropathic pain is a difficult to treat disorder arising from central or peripheral nervous system lesions. The etiology of neuropathic pain consists of several overlapping pathways converging into an exaggerated pain state with symptoms such as allodynia and hyperalgesia. One of these pathways involves activation of spinal cord microglia and astrocytes, which drive and maintain the inflammatory response following the lesion. These cells are a potential target for drugs for neuropathic pain relief. In this current study, we investigated the dose-effect relationship of the tissue protective peptide ARA 290, derived from the tertiary structure of erythropoietin, on allodynia and concurrent spinal cord microglia and astrocytes.

Results

Following a spared nerve injury in rats, vehicle or ARA290 (administered in either one of 4 doses: 3, 10, 30 and 60 μg/kg) was administered on days 1, 3, 6, 8 and 10. ARA290 exerted a dose–response effect by significantly reducing mechanical allodynia up to 20 weeks when compared to vehicle. The reduction of cold allodynia was significant up to 20 weeks for the doses 3, 10, 30 and 60 μg/kg when compared to vehicle. The effect 10 and 30 μg/kg ARA290 and vehicle on the microglia response (iba-1-immunoreactivity, iba-1-IR) and astrocyte reaction (GFAP-immunoreactivity, GFAP-IR) was investigated in animals surviving 2 (group 1) or 20 (group 2) weeks following lesion or sham surgery. In group 1, significant microglia reactivity was observed in the L5 segment of the spinal cord of animals treated with vehicle when compared to sham operated, while animals treated with 10 or 30 μg/kg did not show a increase. In group 2, a more widespread and increased microglia reactivity was observed for animals treated with 0 and 10 μg/kg when compared to sham operated animals, indicated by involvement of more spinal cord segments and higher iba-1-IR. Animals treated with 30 μg/kg did not show increased microglia reactivity. No difference in astrocyte reaction was observed.

Conclusions

The erythropoietin-analogue ARA290 dose-dependently reduced allodynia coupled to suppression of the spinal microglia response, suggestive of a mechanistic link between ARA290-induced suppression of central inflammation and relief of neuropathic pain symptoms.

【 授权许可】

   
2014 Swartjes et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Baron R, Binder A, Wasner G: Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010, 9:807-819.
• [2]Costigan M, Scholz J, Woolf CJ: Neuropathic pain: a maladaptive response of the nervous system to damage. Ann Rev Neurosci 2009, 32:1-32.
• [3]Echeverry S, Wu Y, Zhang J: Selectively reducing cytokine/chemokine expressing macrophages in injured nerves impairs the development of neuropathic pain. Exp Neurol 2013, 240:205-218.
• [4]Austin PJ, Kim CF, Perera CJ, Moalem-Taylor G: Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis. Pain 2012, 153:1916-1931.
• [5]Zhang J, De Koninck Y: Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem 2006, 97:772-783.
• [6]Jin SX, Zhuang ZY, Woolf CJ, Ji RR: p38 Mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003, 23:4017-4022.
• [7]Mika J, Osikowicz M, Rojewska E, Korostynski M, Wawrzczak-Bargiela A, Przewlocki R, Przewlocka B: Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur J Pharmacol 2009, 623:65-72.
• [8]Obata H, Sakurazawa S, Kimura M, Saito S: Activation of astrocytes in the spinal cord contributes to the development of bilateral allodynia after peripheral nerve injury in rats. Brain Res 2010, 1363:72-80.
• [9]Tanga FY, Raghavendra V, DeLeo JA: Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Intl 2007, 45:397-407.
• [10]Romero-Sandoval A, Chai N, Nutile-McMenemy N, DeLeo JA: A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. Brain Res 2008, 1219:116-126.
• [11]Zhuang ZY, Gerner P, Woolf CJ, Ji RR: ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114:149-159.
• [12]Wang W, Wang W, Mei X, Huang J, Wei Y, Wang Y, Wu S, Li Y: Crosstalk between spinal astrocytes and neurons in nerve injury-induced neuropathic pain. PLoS ONE 2009, 4:e6973.
• [13]Govrin-Lippmann R, Devor M: Ongoing activity in severed nerves: source and variation with time. Brain Res 1978, 159:406-410.
• [14]Ren K, Dubner R: Interactions between the immune and nervous systems in pain. Nat Med 2010, 16:1267-1276.
• [15]Wu G, Ringkamp M, Hartke TV, Murinson BB, Campbell JN, Griffin JW, Meyer RA: Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci 2001, 21:RC140.
• [16]Leung L, Cahill C: TNF-alpha and neuropathic pain - a review. J Neuroinflamm 2010, 7:27. BioMed Central Full Text
• [17]Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10:1361-1368.
• [18]DeLeo JA, Colburn RW, Nichols M, Malhotra A: Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996, 16:695-700.
• [19]DeLeo JA, Colburn RW, Rickman AJ: Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res 1997, 759:50-57.
• [20]Mao-Ying QL, Wang XW, Yang CJ, Li X, Mi WL, Wu GC, Wang YQ: Robust spinal neuroinflammation mediates mechanical allodynia in walker 256 induced bone cancer rats. Mol Brain 2012, 5:16. BioMed Central Full Text
• [21]Del Valle L, Schwartzman RJ, Alexander G: Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. Brain Behav Immun 2009, 23:85-91.
• [22]Hua XY, Svensson CI, Matsui T, Fitzsimmons B, Yaksh TL, Webb M: Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur J Neurosci 2005, 22:2431-2440.
• [23]Toda S, Sakai A, Ikeda Y, Sakamoto A, Suzuki H: A local anesthetic, ropivacaine, suppresses activated microglia via a nerve growth factor-dependent mechanism and astrocytes via a nerve growth factor-independent mechanism in neuropathic pain. Mol Pain 2011, 7:2. BioMed Central Full Text
• [24]Zhang X, Xu Y, Wang J, Zhou Q, Pu S, Jiang W, Du D: The effect of intrathecal administration of glial activation inhibitors on dorsal horn BDNF overexpression and hind paw mechanical allodynia in spinal nerve ligated rats. J Neural Transm 2012, 119:329-336.
• [25]Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A: ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain. An experimental study in rats and β-common receptor knockout mice. Anesthesiology 2011, 115:1084-1092.
• [26]Swartjes M, Niesters M, Heij L, Dunne A, Aarts L, Hand CC, Kim HS, Brines M, Cerami A, Dahan A: Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131). PLoS ONE 2013, 8:e71326.
• [27]Brines M, Patel NSA, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A: Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008, 105:10925-10930.
• [28]Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie Q, Smart J, Su-Rick C, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A: Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004, 101:14907-14912.
• [29]Brines M, Cerami A: Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Int Med 2008, 264:405-432.
• [30]Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M: Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006, 12:153.
• [31]Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters J, Vogels O, Brines M, Cerami A, Dahan A: Safety and efficacy of ARA290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double blind, pilot study. Mol Med 2013, 18:1430-1436.
• [32]Ahmet I, Tae HJ, Brines M, Cerami A, Lakatta EG, Talan MI: Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy. J Pharmacol Exp Ther 2013, 345:446-456.
• [33]Coldewey SM, Khan AI, Kapoor A, Collino M, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE: Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int 2013, 84:482-490.
• [34]Ueba H, Shiomi M, Brines M, Yamin M, Kobayashi T, Ako J, Momomura SI, Cerami A, Kawakami M: Suppression of coronary atherosclerosis by helix B surface peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin. Mol Med 2013, 19:195-202.
• [35]Niesters M, Swartjes M, Heij L, Brines M, Cerami A, Dunne A, Hoitsma E, Dahan A: The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Exp Opin Orphan Drugs 2012, 1:77-87.
• [36]Brines M, Cerami A: The receptor that tames the innate immune response. Mol Med 2012, 18:486-496.
• [37]Gwak YS, Kang J, Unabia GC, Hulsebosch CE: Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol 2012, 234:362-372.
• [38]Iwasaki R, Matsuura Y, Ohtori S, Suzuki T, Kuniyoshi K, Takahashi K: Activation of astrocytes and microglia in the C3-T4 dorsal horn by lower trunk avulsion in a rat model of neuropathic pain. J Hand Surg 2013, 38:841-846.
• [39]Beggs S, Salter MW: Stereological and somatotopic analysis of the spinal microglial response to peripheral nerve injury. Brain Behav Immun 2007, 21:624-633.
• [40]Zhang F, Vadakkan K, Kim S, Wu LJ, Shang Y, Zhuo M: Selective activation of microglia in spinal cord but not higher cortical regions following nerve injury in adult mouse. Mol Pain 2008, 4:15. BioMed Central Full Text
• [41]Graven-Nielsen T, Arendt-Nielsen L: Assessment of mechanisms in localized and widespread musculoskeletal pain. Nat Rev Rheumatol 2010, 6:599-606.
• [42]Milligan ED, Twining C, Chacur M, Biedenkapp J, O’Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003, 23:1026-1040.
• [43]Hinojosa A, Garcia-Bueno B, Leza J, Madrigal J: CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflamm 2011, 8:77. BioMed Central Full Text
• [44]Van Steenwinckel J, Reaux-Le Goazigo A, Pommier B, Mauborgne A, Dansereau MA, Kitabgi P, Sarret P, Pohl M, Mélik Parsadaniantz S: CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J Neurosci 2011, 31:5865-5875.
• [45]Tenorio G, Kulkarni A, Kerr BJ: Resident glial cell activation in response to perispinal inflammation leads to acute changes in nociceptive sensitivity: implications for the generation of neuropathic pain. Pain 2013, 154:71-81.
• [46]Milligan ED, Watkins LR: Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
• [47]Suter MR, Papaloïzos M, Berde CB, Woolf CJ, Gilliard N, Spahn DR, Decosterd I: Development of neuropathic pain in the rat spared nerve injury model is not prevented by a peripheral nerve block. Anesthesiology 2003, 99:1402-1408.
• [48]Shankarappa SA, Tsui JH, Kim KN, Reznor G, Dohlman JC, Langer R, Kohane DS: Prolonged nerve blockade delays the onset of neuropathic pain. Proc Natl Acad Sci U S A 2012, 109:17555-17560.
• [49]Campana WM, Li X, Shubayev VI, Angert M, Cai K, Myers RR: Erythropoietin reduces Schwann cell TNF-α, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 2006, 23:617-626.
• [50]Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.
• [51]Watson C, Paxinos G, Kayalioglu G: The spinal cord: a christopher and dana reeve foundation text and atlas. Amsterdam: Elsevier; 2009.